CGON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CG Oncology Inc (CGON) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline and a strong cash position, the recent insider selling, lack of immediate trading signals, and current price decline suggest waiting for a more favorable entry point.
The MACD is positive and contracting, suggesting weakening bullish momentum. RSI is neutral at 64.581, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The price is near key support at 59.074, but the pre-market decline of -5.78% and regular market drop of -1.95% indicate short-term bearish sentiment.
Analysts have consistently raised price targets, with the latest at $80, citing strong progress in clinical trials and a large addressable market.
The company has a robust cash position of $903 million, sufficient to fund operations until
Revenue growth of 254.4% YoY in FY and 409.21% YoY in Q4 2025 indicates strong financial momentum.
Insiders are selling heavily, with a 1311.54% increase in selling activity over the last month.
The stock has a 40% chance to decline by -1.21% in the next day and -3.88% in the next week.
Gross margin dropped significantly (-32.21%), indicating operational inefficiencies.
In Q4 2025, revenue increased by 409.21% YoY, and net income improved by 29.91% YoY, though still negative at -$41.31M. EPS improved to -0.52, up 13.04% YoY. However, gross margin dropped to -32.21%, reflecting challenges in cost management.
Analysts are bullish, with multiple firms raising price targets (latest at $80) and maintaining Buy ratings. They highlight the company's progress in clinical trials, a favorable competitive landscape, and a large addressable market for its lead candidate, cretostimogene.
